High Molecular Weight Hyaluronic Acid (Hyalubrix/HyalOne) for Treating Symptomatic Hip Osteoarthritis
Alberto Migliore1*, Gianfranco Gigliucci1, Sandro Tormenta2, Angelo De Cata3, Luca Gallelli4, Giovanni Iolascon5

1Rheumatology Unit and Research Center, S. Pietro Fatebenefratelli Hospital, Rome, Italy
2Radiology Unit, S. Pietro Fatebenefratelli Hospital, Rome, Italy
3Department of Medical Sciences, Division of Internal Medicine and Rheumatology Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (FG), Italy
4Chair of Pharmacology Department of Health Science, University of Catanzaro School of Medicine, and Operative Unit of Clinical Pharmacology and Pharmacoovigilance, Azienda Ospedaliera MaterDomini, Catanzaro, Italy
5Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Naples, Italy

ABSTRACT
Hip osteoarthritis (OA) causes a set of symptoms that may lead to severe patient impairment, social isolation and morbidity, especially in the elderly. Eventually, patients become candidates for total hip replacement (THR); yet surgery may cause morbidity, increase costs and too risky in some cases. Viscosupplementation (VS) by intra-articular hyaluronic acid (HA) injection has been shown to be effective to treat symptoms consequent to knee OA. VS is a viable option to treat hip OA too, provided that appropriate techniques are used to inject HA into the articular space. To this end, ultrasound-guided approaches have been developed that allow appropriate intra-articular injection eliminating the risk of exposure to ionizing radiation entailed by fluoroscopy. This review summarizes the results of clinical investigations concerning the use of a high molecular weight HA formulation, Hyalubrix/HyalOne, for treating hip OA symptoms. These results show that Hyalubrix/HyalOne has an enhanced safety profile, is effective from the first injection, significantly reduces NSAIDs consumption, and can be used for repeated therapy cycles over more years as a conservative therapy to delay THR. Nevertheless, it must be also considered that a significant placebo effect linked to intra-articular injections may exist, thus reducing the magnitude of HA benefits.

Keywords
Hyaluronic acid
Hyal osteoarthritis
Total hip replacement
Viscosupplementation
Hyalubrix
Joint arthropathies

Hip Osteoarthritis
Osteoarthritis (OA) is the most common cause of joint pain in adults, particularly among the elderly. Hip OA pain may interfere with a patient’s ability to perform routine daily activities: As the hip is a weight-bearing joint, problems caused by hip OA are usually disabling and lead to social isolation; further, hip OA is a frequent cause of morbidity. Prevalence of hip OA is about 17% in white males and 9% in white women over 60 years of age. Treatment aims to relieve pain and to preserve or restore joint mobility, it may be either non-pharmacological or pharmacological, and may involve surgery. Pharmacological treatment includes acetaminophen as a first option, followed by NSAIDs, at the lowest effective dose, to be used in patients who respond inadequately. Patients showing a gastrointestinal risk profile may be treated with non-selective NSAIDs associated with a gastroprotective agent, or a selective COX-2 inhibitor. Finally, patients in whom NSAIDs, including COX-2 selective inhibitors, are ineffective and/or poorly tolerated or contraindicated, may be treated with opioid analgesics, with or without acetaminophen. Any hip OA pharmacological treatment must be protracted over time, possibly forever, raising concerns about short- and long-term side effects of medications, as well as
involving a continuous economic burden, either for the patient or the national health systems. Surgery is regarded as the last option when other approaches have failed; nonetheless, total hip replacement (THR) is becoming more common in Western countries. THR has a 90% success rate, yet it is associated with morbidity including infection, blood clots, loosening, dislocation, nerve and blood vessel injury. Furthermore, the mortality rate consequent to THR ranges from 0.13-0.33% in the United States to 2.2% in Italy. Accordingly, treatment of symptomatic OA should aim to delay surgery while guaranteeing the patient an acceptable quality of life.

**Viscosupplementation using Hyaluronic Acid (HA)**

Recent guidelines concerning non-pharmacological interventions for OA, based on results achieved in treatment of knee OA, indicate that hyaluronic acid viscosupplementation is appropriate for treating hip OA patients not responding to conventional analgesic or pharmacological treatment alternatives.

Hyaluronic acid, also referred to as hyaluronan or sodium hyaluronate, is the most abundant glycosaminoglycan in mammalian tissue. HA consists of long chains (up to 30 μm) of repeating disaccharide units of N-acetylglucosamine and glucuronic acid. The largest quantity is found in the synovial fluid (SF) of the diarthrodial joints, with concentrations ranging between 0.5 and 4 mg/mL; here, molecular weight (MW) of HA chains ranges from 2 to 10 MDa. Under dynamic loading, non-ionic weak forces between HA molecules confer to HA unique non-Newtonian rheological properties, including shear thinning and reduction of viscosity; this confers SF outstanding visco-elasticity, shock-absorbing and lubricating properties, particularly during high shear or compression conditions. Joint arthropathies, including OA, are associated with a reduction of the molecular weight and concentration of hyaluronan in the synovial fluid, as inflammatory cytokines adversely affect the metabolism of HA-producing fibroblasts, leading to the synthesis of HA with a smaller molecular weight. HA MW reduction, coupled with its dilution because of increased synovial membrane permeability, causes SF rheological properties to worsen, further contributing to OA progression.

Based on these observations, HA viscosupplementation by intra-articular injection was introduced as an OA therapeutic approach. Viscosupplementation involves the supplementation or replacement of the SF with exogenous HA with a higher MW than that of endogenous HA or subjected to cross-linking to enhance its rheological properties. This strategy can be adopted to restore or at least improve SF viscoelasticity, decrease symptoms, and improve joint functionality. Since then, HA has been intensively used as a viscosupplementing agent mainly to treat symptoms of knee OA. The higher MW as well as any crosslinking increase HA degradation time, favoring its persistence in the SF. Accordingly, different HA formulations used for intra-articular injection to treat OA may display significantly different characteristics and effects, and their safety and performance should be assessed on a case-by-case basis through long-term, comparative studies.

**Hyalubrix /HyalOne: A High MW HA Viscosupplementing Formulation**

One high MW HA formulation, Hyalubrix/HyalOne (Fidia Farmaceutici S.p.A., Abano Terme, Padova, Italy) has been extensively used as a viscosupplementing agent for intra-articular injection in different forms of joint OA. Hyalubrix is a 1.5% (15 mg/ml) solution of non-modified HA obtained by biofermentation, possessing a molecular weight within the 1.5-2.0 MDa range. Hyalubrix (2 ml / 30 mg) and HyalOne 4ml / 60 mg) are both available on the market as three injections and one single injection regimen respectively. HA formulations with this MW show rheological properties resembling those of native HA in the SF, as their crossover point (~0.8 Hz) is significantly closer to that observed in joint fluid samples (~0.4 Hz) compared to lower MW formulations (~11 Hz) also used for intra-articular therapy. High MW HA, having longer molecular chains, may display more interactions with natural phospholipids, contributing to increased lubricating power and may be more effective in preventing fluid drainage from the joint, thanks to its greater outflow buffering effect. Finally, the clearance time of HA in the 1.5-2.0 MDa range was found to be significantly longer (120 hrs) than that of HA having a <1 MDa MW (60 hrs) when injected in rabbit knee joints. Hyalubrix/HyalOne, therefore, was considered an optimal viscosupplementing agent candidate.

Indeed, its intra-articular administration to treat OA symptoms was tested in several controlled and observational clinical trials. A multicenter, large-scale, observational study by Schieb involved 1523 patients. In this study, 81.3% of subjects suffered from knee OA, while the others were affected by traumatic arthropathies. Patients received three weekly Hyalubrix intra-articular injections and were observed for a maximum of six weeks. Intensity of pain and mobility were evaluated according to a Visual Analogue Scale (VAS), both at the start and end of treatment. Patients experienced a significant pain reduction; upon conclusion of administration of Hyalubrix, 91.2% of patients reported significantly less pain and 85.3% reported significantly better, or completely recovered mobility than before beginning treatment. In 2011 Foti and colleagues carried out another large-scale (47 centers, 1266 patients, 1707 OA joints), prospective observational study, involving intra-articular injection of Hyalubrix in different OA affected synovial joints (knee: 82.0% of total joints being treated; hip: 9.0%; shoulder: 6.3%; tibio-tarsal joint: 1.5%; and
trapeziometacarpal joint: 1.2%). Participants received intra-articular HA (30 mg/2 ml) in one or more joints, as required, once a week for three consecutive weeks. The participants were then assessed two weeks after the final injection to evaluate the variation in efficacy parameters compared to the baseline visit. Mean VAS for joint pain in motion significantly decreased over the study period for all joints, and a similar (but smaller) change occurred in VAS for pain at rest. Further, a significant improvement in motor function was observed, as indicated by the Stanford Health Assessment Questionnaire scores. The number of patients using NSAIDs decreased over the study period (only 4% of subjects were using them at the follow-up visit). Three weekly injections, even if at different doses, were also found to be effective in alleviating pain in two investigations concerning intra-articular injection of 7.5 mg / 0.5 ml or 15 mg /1 ml Hyalubrix 30 mg in OA trapeziocarpal joints34,35. Patients (N=16, 32 joints) in the study by Ingegnoli experienced a significant decrease in VAS pain after only 2 weeks of treatment and this result was maintained at week 24; those treated by Di Sante (N=31, 31 joints) experienced a statistically significant VAS score reduction at 1 and 3 months, but not at the 6-month follow-up. One 30 mg /2 ml Hyalubrix intra-articular injection per week for three weeks was also found to be effective in reducing subjective pain and WOMAC scores of patients (N=14, 14 joints) suffering knee OA; objective optoelectronic digital analysis of gait confirmed a significant improvement of a set of biomechanical parameters36. Filardo and colleagues17 compared the injection of Platelet Rich Plasma (PRP) to that of Hyalubrix 30 mg for treating symptoms of knee OA. The investigators found at all follow-up visits (2, 6, and 12 months after treatment) that three weekly HA injections (2 ml /30 mg each, N=89 patients and joints) were as effective as three weekly 5 ml PRP injections (N=94 patients and joints) where the International Knee Documentation Committee (IKDC) subjective score, the Knee Injury and Osteoarthritis Outcome Score, their quality of life (EuroQol score), the Tegner score, the transpatellar circumference, and the joint range of motion were concerned.

Priano and Guelfi38 investigated how post-meniscectomy Hyalubrix 30 mg injection affected the post-surgical course of patients, finding that patients treated with HA (N=51) experienced significantly less pain while walking, at rest, during activity, and at pressure, and had better joint mobility and functional evaluation according to the Lysholm score than patients undergoing no HA injections (N=49).

The cited studies showed that Hyalubrix/HyalOne had quite a good safety and tolerability profile; adverse events, mostly transient and having minor clinical significance, were those usually observed with HA formulations39 such as reddening, itching, or pain at the injection site. Incidence of adverse events in the Schieb12 and Foti13 large trials varied between 0.5% and of 0.8% (Table 1).

### Table 1: List of the most relevant clinical studies using Hyalubrix for viscosupplementation of other joints.

<table>
<thead>
<tr>
<th>First author (year)</th>
<th>Study type</th>
<th>Product</th>
<th>Dose</th>
<th>N° patients</th>
<th>Follow-up</th>
<th>Primary endpoint</th>
<th>Main finding(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smidtene 200734</td>
<td>Observational</td>
<td>Hyalubrix</td>
<td>3 x 2 ml (2 ml per week)</td>
<td>14</td>
<td>6 weeks</td>
<td>Pain assessed by the numerical rating scale (NRS) and WOMAC osteoarthritis index</td>
<td>Gait analysis of patients with grade II or grade III osteoarthritis revealed significant improvement of most cinematics and kinetics parameters. Amelioration of symptoms (pain and WOMAC index).</td>
</tr>
<tr>
<td>Foti 201133</td>
<td>Observational</td>
<td>Hyalubrix</td>
<td>3 x 2 ml (2 ml per week)</td>
<td>1266</td>
<td>5 weeks</td>
<td>Safety (number of adverse events) and details of usage of the IA sodium hyaluronate syringe device</td>
<td>The adverse event (AE) rate was 0.8% (95% CI, 0.4 to 1.5). No serious adverse events occurred. Co-administration of local anesthesia was required by up to 10% of patients. Statistically significant improvements in VAS, HAQ, and EuroQol were recorded in multiple joints.</td>
</tr>
<tr>
<td>Ingegnoli 201134</td>
<td>Observational</td>
<td>Hyalubrix</td>
<td>3 x 2 ml (2 ml per week)</td>
<td>16</td>
<td>24 weeks</td>
<td>Treatment impact assessed by VAS pain measurement</td>
<td>Significant clinical improvement was obtained by the decrease in visual analog scale for pain and this result is maintained at week 24. The Dreiser’s index also decreased after week 2 and remained stable after 8 months. Power Doppler signal significantly decreased after 2 weeks of treatment, even if this result was not maintained at week 24. No significant decrease in the synovial hypertrophy score was observed during the study.</td>
</tr>
<tr>
<td>Di Sante 201134</td>
<td>Case series</td>
<td>Hyalubrix</td>
<td>3 x 1 ml (1 ml per week)</td>
<td>31</td>
<td>6 months</td>
<td>Evaluation of the mean VAS score for pain and of the mean Duruöz Hand Index (DHI) for hand functionality</td>
<td>Statistically significant VAS score reduction was observed at 1 and 5 months after the end of treatment, but not at 6-month follow-up. No statistically significant difference was found on the DHI total score at 1 and 6-month follow-ups.</td>
</tr>
<tr>
<td>Filardo 201535</td>
<td>Randomized controlled</td>
<td>Hyalubrix</td>
<td>3 x 2 ml (2 ml per week)</td>
<td>192</td>
<td>12 months</td>
<td>International Knee Documentation Committee (IKDC) subjective score improvement at the 12-month follow-up</td>
<td>PRP injections were found to cause more post-injection swelling and pain compared to HA injections. Both treatments were effective in improving knee functionality and in reducing symptoms. Since PRP does not provide clear clinical advantages with respect to HA, it should not be preferred to viscosupplementation to treat patients affected by knee cartilage degeneration and osteoarthritis.</td>
</tr>
</tbody>
</table>
possibly because of the anatomic differences between the two joints that make injection in the hip more difficult and present more risk of harming delicate structures such as vessels and nerves. Hip injection by the hands-free technique is prone to errors, leading to not injecting HA into the articular space; alternatively, fluoroscopy is expensive, time-consuming, and exposes the patient and the physicians to unwanted radiation, and its use should be limited to few applications. To overcome these limitations, our group opted for performing HA injections under ultrasound (US) guidance, according to an anterosuperior approach that has been standardized over time. In short, the approach involves using an US transducer together with a sterile biopic target device while patients are placed supine with the hip at 15-20° internal rotation: the hip joint is scanned according to an anterior parasagittal approach, lateral to the femoral vessels. The transducer is aligned with the long axis of the femoral neck, comprising the acetabulum and the femoral head. The injection is performed by inserting a 20-gauge (9 cm) spinal needle into the biopsy guide: using biopsy real-time guidance software, the needle is advanced into the anterior capsular recess, at the level of the femoral head and, when in contact with it, is retracted by 1 mm before starting the injection. Verification of injection into the articular space is allowed by real-time monitoring (direct visualization of viscous fluid or air bubbles) and power Doppler imaging (flow signals in intra-articular recess). The color Doppler vision also allows the physician to avoid blood vessels. An open study on a large register of 1906 patients (4002 injections) undergoing HA injection according to this approach confirmed this technique is well tolerated with few, and exclusively local, side effects. The technique was shown to facilitate achieving an accurate delivery of the injected product as well as the repeatability of the injections, allowing long-term management of hip OA. Indeed, the low incidence of adverse events (<5%) observed was similar to the safety results obtained by Tikiz and colleagues by fluoroscopic guidance, indicating US guidance achieves successful IA injection of the medication.

Results by Our Group

Preliminary results concerning Hyalubrix/HyalOne US-guided intra-articular injection for treating Hip OA were provided in 2008 at the OARSI (OsteoArthritis Research Society International) World Congress on Osteoarthritis, describing how 239 adults (271 joints), ambulatory patients suffering from hip OA grade 1 to 3 according to Kellgren and Lawrence, were prospectively recruited and injected using (4 ml / 60 mg) of HyalOne every six months or, if needed because of their clinical conditions, every three months. Patients were then followed-up every three months up to 18 months after the first injection. Treatment was shown to be effective, since both the Lequesne index and the VAS pain score were observed to be significantly reduced at all time points versus baseline for all assessment criteria. NSAIDs consumption was also found to be significantly lower at all time points versus that recorded during the month preceding the first injection. No local or systemic adverse events were reported. Such observations suggested continuous intra-articular use of Hyalubrix/HyalOne in hip OA patients was effective, even on a long-term basis, to maintain the positive effects obtained after the first injection, allowing the reduction of NSAID consumption. These findings were confirmed by a prospective cohort study including Kellgren-Lawrence (KL) grade I, II, III, or IV symptomatic hip OA patients aged ≥40 years and experiencing pain for at least one year. The study involved 120 patients that were subjected to 4ml/60 mg intra-articular HyalOne injections every six months and, if needed, to additional injections every three months, and were followed up to 18 months after the first injection. Scores collected were the same used during the previous study; a statistically significant reduction in algofunctional indexes was observed even at 3 months after the first injection. At 12 months, 80% of the patients achieved a ≥ 30% decrease in symptoms. These results were maintained over time through cyclical ultrasound guided injections, with one administered at least every 6 months. Adverse events were mild, transient, and observed in about 3% of injections.

Therapeutic effectiveness in hip OA symptoms treatment by intra-articular injections of Hyalone was also confirmed by a double-blind, controlled trial aimed to investigate their effect versus that of local analgesia induced by injecting mepivacaine. Hip OA patients were included if aged >40 years and suffering from VAS pain ≥ 4 persisting for at least one month before the first injection. Patients were randomized to be treated either by two 60 mg/4 ml Hyaline or 20 mg/1 ml mepivacaine hydrochloride US-guided intra-articular injections carried out one month apart. The primary objective of the study was to compare the Lequesne algofunctional index of the two groups at 6 months (26 weeks) after the first injection. Secondary objectives included comparing the two groups for pain intensity, NSAIDs consumption, and overall subjective and objective global assessment. Forty-two patients were recruited, 85.7% of whom were affected by KL Grade III OA. Concerning the Lequesne’s Index, both treatment groups significantly improved at 3 and 6 months versus baseline. The HA was significantly superior to mepivacaine at both time points; pain also significantly improved versus baseline and was significantly less in the HA group at both follow-up visits. Patients in both groups showed decreased NSAIDs consumption, and in both groups subjective and objective global assessment scores were significantly better at both follow-up visits than at baseline for both groups.
groups. Concerning these parameters, the two groups did not display statistically significant differences. One HA patient experienced intra-articular pain after injection that resolved after 7 days with acetaminophen 2 g/day. One mepivacaine patient suffered from mildly intense pain at the injection site that resolved spontaneously after 36 hours. Results from the prospective study previously mentioned concerning a cohort of hip OA patients treated by HyalOne injections showed that the number of subjects who, at the end of the 18-month follow-up period, had to undergo THR was low (8 patients out of 239, for a THR rate of about 3%). Consistent with indications of the EULAR agenda5 prompting researchers to assess whether viscosupplementation can slow the progression of osteoarthritis and/or to delay joint replacement, a further study was therefore carried out to compare the recommendations for THR at baseline, provided by a group of independent orthopedists, with the actual rate of THR received by the patients during a cohort 48-month follow-up52. Six orthopedists each independently assessed whether 176 patients suffering from hip OA, treated with US-guided intra-articular injections (60 mg / 4ml every six months, with additional injections every three months if needed) of HyalOne were candidates for THR according to their baseline age, body mass index, pain VAS, Lequesne index, global patient assessment, global physician assessment, nonsteroidal anti-inflammatory drug intake, and hip X-ray. At 24 months, 159 out of 176 (90 %) patients did not undergo THR. At 48 months, 82% (N=144) of patients had avoided THR. At 24 months, only 17 out of the 93 patients considered candidates for THR (that is, in which 4, 5, or 6 orthopedic surgeons agreed that the patient was a suitable candidate for THR) had undergone THR corresponding to a 82% survival rate. At 48 months, this rate had decreased to 66%. Patients for whom respectively 3, 2, 1 or no surgeons agreed that the patient was a candidate for THR did not undergo arthroplasty. Thus, HyalOne US-guided intra-articular injection was shown to delay THR in the context of actual management of symptomatic hip OA patients, indicating viscosupplementation using HyalOne may be effectively carried out to delay proposing a patient for THR.

Given these results, a long-term follow-up study53 was recently carried out and reported the efficacy of US-guided (60 mg / 4 ml) HyalOne injection in a large population of hip OA patients, repeated at least 2 times per year up to seven years. Data were collected from the ANTIAGE registry47. Values of Lequesne index, pain VAS, NSAIDs intake, global medical and patient assessments were evaluated every three months from the baseline to the end of the follow-up, seven years later. Radiographic evaluation was carried out every 24 months through standard X-ray. The inclusion criteria were: age ≥18 years, symptomatic hip osteoarthritis for one year, and follow-up ≥ 84 months. The 1022 included patients were categorized by age, class, gender, and body mass index (BMI). All groups showed a statistically significant reduction at all time points, compared to baseline, of all scores under assessment, with slight differences in the subgroups of overweight, obese, and over 70-year-old patients. Pain improvement was greater (46.7%) in patients younger than 40, and lower, but still clinically significant (25%) in patients older than 70, with other age classes scoring intermediate values. Older patients (>80 years) experienced about a 45% improvement in their functional scores at the last follow-up visit, with other ages experiencing a similar rate (from 34% to 50%). In any case, all patients, whatever their age or BMI, experienced a significant improvement for all scores under assessment at six months after treatment and, most significantly, repeating HA injections allowed the maintenance of such improvements for the following six years and a half. Over seven years, no systemic or severe local side effects were ever reported. Some patients experienced pain after injection that lasted from several hours to few days, confirming previous data49,50,52. In conclusion, the study showed that HyalOne, while displaying an excellent safety profile, did not lose efficacy over time even after repeated injections over more years.

Additional Studies from Other Groups Working with Hyalubrix/HyalOne on Hip OA

Other investigations from independent researchers support the conclusion that Hyalubrix/HyalOne intra-articular injection is a consistent approach to treat hip OA symptoms, allowing repeated injections over time and postponing replacement surgery. Results from the study already cited by Foti et al.33 who treated successfully 1707 OA joints, included 154 hips. Paoloni et al.54 performed a prospective, open study in 20 hip OA patients to assess the clinical effects of 3 weekly US-guided intra-articular injections of 30 mg/2 ml Hyalubrix on pain and function at 1, 3, and 6-month follow-ups through VAS and WOMAC scores, as well as changes in the kinematics and kinetics of gait at the 6-month follow-up, using a gait analysis system based on recordings collected using infrared video cameras55-57. At all time points, pain, as well as stiffness and disability, significantly decreased versus baseline. Three months after injections patients walked with higher cadence and stride length and had a significant increase in the pelvic tilt at heel contact and in hip flexion–extension moments at loading response sub-phases of gait cycle. De Lucia et al.58 carried out an observational study involving 95 hips of 91 patients, 80 affected by primary OA, 15 suffering from OA secondary to inflammatory rheumatic diseases. Patients were randomly assigned to receive a US-guided intra-articular injection using a medium-MW HA derivative (Hylan G-F 20; Synvisc; Genzyme, 56 hips) or Hyalubrix/HyalOne (39 hips). Injections were carried out at recruitment, at 1 and 2 months, and then every 6 months
thereafter. Patients were assessed at inclusion, and then after 1, 6, 12, and 24 months after the last injection. A significant decrease of VAS and WOMAC total scores was observed after only 1 month. Such improvement was maintained over 2 years independently from the radiological degree of OA, with both HA derivatives; yet improvement was faster in the group treated with Hyalubrix. Mauro et al.\(^\text{36}\) enrolled 40 patients affected by hip OA who were subjected to three US-guided injections of Hyalubrix 45 days apart, combined with three physical therapy sessions a week, including proprioceptive rehabilitation of the lower limbs, gait training, balance training, for up to a total of 30 sessions (10 weeks), starting from one week after the first injection. Examinations were carried out after each intra-articular injection and 45 and 60 days after the last injection. Pain perceived by patients during activity dropped significantly already after the first injection. This result was maintained at all following visits. Significant improvements were also observed in the evaluation in hip disability, OA-related pain at rest, daily functioning and NSAIDs intake, confirming the effectiveness of combined Hyalubrix injection and physical therapy Table 2).

**Discussion**

Taken together, the results of the studies summarized in the previous paragraphs show that intra-articular injection of Hyalubrix/HyalOne to treat pain symptoms and disability consequent to hip OA is beneficial, starting from the very first injection, and allows for repeated therapy cycles, at time intervals of months, and over more years, to maintain the beneficial effects over time.

The maintenance of Hyalubrix/HyalOne effects over the time occurring between two consecutive injections still calls for a definitive explanation: while HA having the MW of Hyalubrix/HyalOne has a residence time significantly longer than the one exhibited by HA of lower MW, complete

<table>
<thead>
<tr>
<th>First author (year)</th>
<th>Study type</th>
<th>Product</th>
<th>Dose</th>
<th>N(^\circ) patients</th>
<th>Follow-up (months)</th>
<th>Primary endpoint</th>
<th>Main finding(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Migliore 2005(^\text{35})</td>
<td>Open-label, pilot</td>
<td>Hyalgan</td>
<td>2 x 2 mL</td>
<td>14</td>
<td>12</td>
<td>Efficacy of ultrasound-guided intrarticular (IA) injections of Hyalgan assessed by Lequesne index, visual analog scale (VAS) pain measurement and NSAIDs consumption.</td>
<td>Hyalgan at the regimen seems to be a safe and efficacious treatment for hip osteoarthritis, with the patients showing functional improvement in response to the treatment.</td>
</tr>
<tr>
<td>Migliore 2006(^\text{36})</td>
<td>Open-label, prospective</td>
<td>Hyal G-F 20</td>
<td>1, 2, or 3 X 2 mL</td>
<td>30</td>
<td>6</td>
<td>Efficacy of US-guided IA injections of Hyal G-F 20 in patients with symptomatic hip OA assessed by Lequesne index, visual analog scale (VAS) pain measurement, and NSAIDs consumption.</td>
<td>No systemic adverse events were observed. Lequesne index, VAS pain score, and NSAIDs consumption showed statistically significant reductions after the treatment compared to baseline.</td>
</tr>
<tr>
<td>Migliore 2008(^\text{37})</td>
<td>prospective, observational, open-label</td>
<td>Hyal G-F 20</td>
<td>1 x 2 mL, given 1 injection every 3 months (if justified)</td>
<td>250</td>
<td>12</td>
<td>Efficacy of US-guided IA injections of Hyal G-F 20 in patients with symptomatic hip OA assessed by Lequesne index, visual analog scale (VAS) pain measurement, and NSAIDs consumption.</td>
<td>Statistically significant reductions in VAS pain scores, Lequesne index scores, and NSAIDs usage were reported at all time points (p &lt; 0.05). No systemic, venous, or severe side effects were observed. Fifty-two local AEs were reported (7.08% per injection) all of which were mild and transient.</td>
</tr>
<tr>
<td>Migliore 2009(^\text{38})</td>
<td>Observational, post-marketing</td>
<td>Hyalubrix/HyalOne</td>
<td>2 x 2 mL (every 3 or 6 months)</td>
<td>344</td>
<td>18</td>
<td>Long-term duration of benefit of US-guided IA injection of Hyalubrix in patient with hip OA, assessed every 3 months by Lequesne index, VAS pain score, and NSAIDs consumption.</td>
<td>Statistically significant reductions in VAS pain, Lequesne index, and NSAIDs consumption were observed at all time points.</td>
</tr>
<tr>
<td>Migliore 2011(^\text{39})</td>
<td>Randomized, double-blind, controlled</td>
<td>Hyalubrix/HyalOne</td>
<td>2 x 2 mL, twice</td>
<td>42</td>
<td>6</td>
<td>Determination of the change in the Lequesne index of the hip, comparing HA with IA mepivacaine at 26 weeks</td>
<td>Hyalubrix-treated patients exhibited significantly reduced Lequesne index scores and visual analog pain scores at 3 and 6 months after treatment compared with the local anesthetic group. Adverse events were minimal.</td>
</tr>
<tr>
<td>Migliore 2012(^\text{40})</td>
<td>Observational, prospective, cohort</td>
<td>Hyalubrix/HyalOne</td>
<td>1 x 4 mL, every 6 months, plus 1 injection every 3 months (if justified)</td>
<td>304</td>
<td>18</td>
<td>Evaluation of the Lequesne algofunctional index over time</td>
<td>Statistically significant reductions in the algofunctional index were observed at 3 months after product administration. At 12 months, 60% of the patients achieved a decrease of at least 20% in symptoms. These results were maintained over time through cyclical and personalized repetition of ultrasound-guided injections, at least one injection every 6 months.</td>
</tr>
<tr>
<td>Migliore 2013(^\text{41})</td>
<td>Retrospective, observational</td>
<td>Hyalubrix/HyalOne</td>
<td>1 x 4 mL, every 6 months, plus 1 injection every 3 months (if justified)</td>
<td>176</td>
<td>48</td>
<td>Frequency and timing of THR in patients suffering from hip OA treated with ultrasound-guided intra-articular injections of Hyalubrix.</td>
<td>Sodium hyaluronate (MW 1,500–5,000 KDa) given by ultrasound-guided injection seems to delay THR for at least 24 months. In 17 of 190 (0%) patients did not undergo THR. At 48 months, 92% (n = 146) of the study population treated with intravertebral hyaluronic acid avoided THR.</td>
</tr>
<tr>
<td>Passino 2017(^\text{42})</td>
<td>Prospective, open-label</td>
<td>Hyalubrix/HyalOne</td>
<td>3 x 2 mL (1 every week)</td>
<td>20</td>
<td>6</td>
<td>Perceived pain as measured via the VAS scale at 1, 3, and 6 months</td>
<td>Subjectively significant reduction in pain was observed after the treatment, and improvements in stiffness, disability measured with the Western Ontario and McMaster Universities osteoarthritis index, and gait kinematics and time-lapse parameters were also observed.</td>
</tr>
<tr>
<td>Migliore 2017(^\text{43})</td>
<td>Retrospective observational</td>
<td>Hyalubrix/HyalOne; Hyalgan, Jointsite, Synchro, SoftREAM, Integaal</td>
<td>Variable number of 2 or 4 mL injections</td>
<td>1906</td>
<td>Every 3 months up to 4 years</td>
<td>Safety (number of adverse events/total injections)</td>
<td>The results show that the treatment was well tolerated, with few, and only local, side effects.</td>
</tr>
<tr>
<td>Migliore 2018(^\text{44})</td>
<td>Prospective, observational, open-label</td>
<td>Hyalubrix/HyalOne</td>
<td>1 x 4 mL, every 6 months, plus 1 injection every 3 months (if justified)</td>
<td>1022</td>
<td>84</td>
<td>VAS scale of perceived pain, Lequesne algofunctional index, NSAIDs consumption</td>
<td>The first study reporting a large cohort of patients with hip osteoarthritis with a long follow-up period (7 years). The confirm that ultrasound-guided viscosupplementation is a suitable therapy for the management of hip osteoarthritis.</td>
</tr>
<tr>
<td>Meurs 2017(^\text{45})</td>
<td>Prospective, open-label</td>
<td>Hyalubrix/HyalOne</td>
<td>3 injections (spaced 45 days)</td>
<td>40</td>
<td>6.5</td>
<td>Pain during activity (VAS scale)</td>
<td>The treatment resulted in a long-lasting statistically significant decrease in the pain perceived by the patients starting from the first visit. Significant improvements were also observed in hip disability, OA-related pain at rest, daily functioning, and NSAIDs intake.</td>
</tr>
</tbody>
</table>
clearance is still expected within a few days\textsuperscript{31}. It is possible that high MW HA, in addition to temporarily restoring SF lubrication and viscoelasticity, may act as a mechanical filter towards inflammatory mediators, reducing their sensitizing effect on nociceptors\textsuperscript{40}.

Results of the above-mentioned studies also show that hip OA patients who benefit from the effect of intra-articular injection of Hyalubrix/HyalOne significantly reduce their NSAID consumption. This, in turn, may also reduce the costs associated with disease management and with the side-effects induced by NSAIDs. Better mobility may lead to improvements in patients’ daily activities, such as work (with productive gain) and self-care (with reduced assistance-related costs). Finally, results of the present study indicate that hip viscosupplementation with Hyalubrix/HyalOne may be effective in delaying THR in hip OA patients and may be considered a conservative treatment to be carried out concomitantly with other non-pharmacological approaches\textsuperscript{14,61} before resorting to arthroplasty, as suggested by the OARSI recommendations\textsuperscript{62,63}. Such a conservative treatment, as shown in the latter study by our group\textsuperscript{53} may be protracted for years without losing its benefit or causing significant incremental side effects.

Of note, it was suggested that a significant placebo effect intrinsic to knee intra-articular injections may exist\textsuperscript{64,66,67,68}, and that the effect size of HA might have been overestimated because of the influence of non-blinded or improperly blinded trials\textsuperscript{45}. In light of this, the possibility that such a placebo effect accounts, at least partially, for the benefits of intra-articular Hyalubrix/HyalOne injections observed in patients with hip osteoarthritis cannot be excluded, and further blinded studies should be carried out to better estimate the HA effect size.

Conclusions

In conclusion, these data support the use of Hyalubrix/HyalOne as a safe and effective background therapy in hip OA. Management of hip OA should involve viscosupplementation, together with other interventions, and orthopedists who do not routinely perform hip injections should be aware of the degree of efficacy which may be achieved by hip viscosupplementation.

References


c14.


